Cleerly, a company focused on transforming the diagnosis of heart disease, has announced positive results from the CERTAIN multicenter clinical trial. The study, published in the European Heart Journal Cardiovascular Imaging, involved 750 patients across five U.S. sites and showcased the significant impact of Cleerly's products on clinical management for individuals suspected of coronary artery disease.
Compared to the standard interpretation of coronary CT angiography (CCTA) by expert physicians, Cleerly's products led to a notable change in clinical decision-making and patient management in over 57% of cases. The comprehensive evaluation offered by Cleerly resulted in a 39% change in coronary stenosis assessment, a 37% reduction in the need for further testing, and a 28% increase in the use of preventive medications.
The study highlighted Cleerly's ability to enhance diagnostic accuracy, reduce unnecessary downstream resource utilisation, and increase the use of preventative medical therapy. Cleerly's products, driven by artificial intelligence and based on advanced non-invasive CT imaging, have consistently demonstrated robust clinical utility across various clinical studies, surpassing historical tests like nuclear SPECT stress testing and FFRCT.
The company's mission is to eliminate heart attacks by setting a new standard of care for heart disease, supported by FDA-cleared solutions grounded in scientific research from over 10 million images and 40,000 patients across 15 years of landmark clinical trials.
Click here to read the original news story.